Les nouveaux anticoagulants en 2024 : développement des inhibiteurs du facteur XI et du facteur XIa (notice n° 660031)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03806cam a2200361 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250121192115.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Bentounes, Nûn K. |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Les nouveaux anticoagulants en 2024 : développement des inhibiteurs du facteur XI et du facteur XIa |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2024.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 69 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | La thrombose reste l’une des principales causes de décès dans le monde. L’histoire de l’anticoagulation a considérablement évolué, passant de médicaments non spécifiques (les héparines et les antivitamines K) à des molécules qui ciblent directement des facteurs de coagulation spécifiques (l’argatroban, le fondaparinux et les anticoagulants oraux directs [AOD]). Au cours des dix dernières années, les AOD se sont imposés dans l’arsenal thérapeutique grâce à leur facilité d’administration, leur profil pharmacologique favorable et au fait qu’ils ne nécessitent pas de surveillance biologique. Les AOD présentent un profil de tolérance plus satisfaisant que celui des antagonistes de la vitamine K. Cependant, le risque de survenue d’événements hémorragiques subsiste et constitue un effet indésirable redouté. De nouveaux anticoagulants ciblant la phase de contact de la coagulation sont actuellement en développement et pourraient permettre de prévenir le risque thrombotique sans altérer l’hémostase physiologique, réduisant ainsi le risque hémorragique. Les données observationnelles et précliniques sur le déficit en facteur XI (FXI) en font une cible thérapeutique prometteuse. L’objectif de cet article est de passer en revue les résultats des différents essais cliniques disponibles à ce jour, qui se focalisent sur l’inhibition du FXI/FXI activé, et de mettre en évidence les défis auxquels cette nouvelle classe thérapeutique d’anticoagulants devra faire face. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Thrombosis remains one of the leading causes of death in the world. The history of anticoagulation has evolved considerably from non-specific drugs ( i.e., heparins and vitamin K antagonists, VKA) to agents that directly target specific coagulation factors ( i.e., argatroban, fondaparinux and direct oral anticoagulants, DOAC). Since the last decade, DOAC are widely used in clinical practice because of their ease to use, their favorable pharmacological profile and the fact that they do not require monitoring. However, despite having a better safety profile than VKA, their bleeding risk is not negligible. New anticoagulants targeting the contact phase of coagulation are currently being developed and could make it possible to prevent the risk of thrombosis without impairing hemostasis. Epidemiological and preclinical data on FXI deficiency make FXI a promising therapeutic target. The aim of this review is to summarize the results of the various clinical trials available that focus on FXI/FXIa inhibition, and to highlight the challenges that this new therapeutic class of anticoagulants will face. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hémostase |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | fibrillation atriale |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | Inhibiteur du facteur XI/facteur XI activé (FXI/XIa) |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anticoagulants |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | maladie veineuse thromboembolique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thrombus |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thromboembolic venous disease |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | haemostasis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | FXI/XIa inhibitor |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | atrial fibrillation |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anticoagulants |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thrombus |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Melicine, Sophie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Céline Martin, Anne |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Smadja, David M. |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gendron, Nicolas |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hématologie | 30 | 3 | 2024-07-23 | p. 191-206 | 1264-7527 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-hematologie-2024-3-page-191?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-hematologie-2024-3-page-191?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux